PA-FRIEND-MTS
Friend MTS is pleased to announce the appointment of Derek Chang to Chief Executive Officer (CEO). A seasoned industry executive with a career spanning three decades, Chang previously served as CEO of NBA China, and has held leadership positions with several recognized sports, media and entertainment providers. He will be based in London.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005316/en/
“It is my privilege to join Friend MTS as we ramp up our innovation of the technology essential to protect the needs of a complex global media industry,” said Chang. “We are at the forefront of rapid changes in consumer behavior, new business models and technology, and will ensure that creators, owners and distributors worldwide will have the formidable tools necessary to protect their valuable content.”
The announcement was made today by Jonathan Friend, Founder, Friend MTS, who previously served as CEO. A visionary in the field of content protection technologies, Friend will serve as Chief Product Officer (CPO) and continue to drive growth through the creation of the company’s advanced proprietary solutions.
“As we continue to innovate with groundbreaking solutions that our valued customers and partners have come to expect, now is the time to transition to our next leader and we are thrilled to welcome Derek to the helm of Friend MTS,” said Friend. “With deep expertise in the global sports and entertainment space, Derek brings invaluable insight to leveraging technology to create an impactful footprint for an ever-evolving media and content ecosystem.”
Prior to leading NBA China’s business, Chang was Head of International Lifestyle Channels for Scripps Networks Interactive, and had served as Executive Vice President, Content, DIRECTV. He also held senior roles for Charter Communications, the YES Network and TCI Communications. Chang currently serves on the board of directors for Liberty Media Corp. and Isos Acquisition Corp., and formerly served on the board of Starz.
Chang was named one of the “50 Most Influential People in Sports Business” by Sports Business Journal , as well as Cablefax Magazine's “Top 100 Executives in Cable.” He holds an MBA from Stanford University and a bachelor's degree in history from Yale University. He is a member of the Committee of 100 and serves on the advisory board of Row New York.
For press use, Friend MTS photo assets can be downloaded here . For more information, please visit www.friendmts.com or follow on LinkedIn and Twitter .
About Friend MTS:
Friend MTS is a leading global provider of innovative content protection technology solutions developed to advance a complex and ever-evolving media industry in collaboration with content owners, broadcasters and operators. With a comprehensive suite of advanced proprietary services ranging from content monitoring, fingerprinting and watermarking to enforcement and IP blocking, Friend MTS provides an end-to-end approach to disrupt real-world piracy and safeguard a worldwide entertainment and media market into the future. Playing an important role in social responsibility, Friend MTS has gifted organizations like the U.S. Department of Homeland Security and the International Center for Missing and Exploited Children (ICMEC) with its award-winning technology to help combat online child abuse. Founded in 2000, Friend MTS is privately held and headquartered in Birmingham, U.K. and Philadelphia, Pennsylvania, with operations throughout Europe, Asia, the Middle East, Africa, Latin America and North America.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005316/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom